In this study, the loss of BAP1 resulted in an abnormal upregulation of SERPINE1 (PAI-1) and hence, SERPINE1 could be a new target for the treatment of BAP1-deficient ccRCC. The gene discussed is BAP1; the disease is nonpapillary renal cell carcinoma.